NKMAX CO., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 03:03 am EDT
Share
NKMAX CO., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 0.00001 million compared to KRW 0.00002 million a year ago. Net loss was KRW 17,279.14 million compared to KRW 16,954.57 million a year ago. Basic loss per share from continuing operations was KRW 439 compared to KRW 489 a year ago. Diluted loss per share from continuing operations was KRW 439 compared to KRW 489 a year ago. Basic loss per share was KRW 439 compared to KRW 489 a year ago.
For the six months, sales was KRW 0.00001 million. Net loss was KRW 30,062.72 million compared to KRW 29,516.68 million a year ago. Basic loss per share from continuing operations was KRW 772 compared to KRW 856 a year ago. Diluted loss per share from continuing operations was KRW 772 compared to KRW 856 a year ago. Basic loss per share was KRW 772 compared to KRW 856 a year ago.
NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.
NKMAX CO., LTD. 
